login

Reduction of suicidality during clozapine treatment of neuroleptic- resistant schizophrenia: impact on risk-benefit assessment

American Journal of PsychiatryPublished 1 February 1995
H.Y. Meltzer, Ghadeer Okayli
Citations439
SJR quartileQ1
SJR score5.27
SNIP3.68

TL;DR

The results suggest a basis for reevaluation of the risk-benefit assessment of clozapine, i.e., that the overall morbidity and mortality of patients with neuroleptic-resistant schizophrenia are less with clozAPine treatment than with typical Neuroleptic drugs because of less suicidality.

Abstract

These results suggest a basis for reevaluation of the risk-benefit assessment of clozapine, i.e., that the overall morbidity and mortality of patients with neuroleptic-resistant schizophrenia are less with clozapine treatment than with typical neuroleptic drugs because of less suicidality. This conclusion also has implications for increasing the use of clozapine with neuroleptic-responsive patients.

Keywords

MedicineNeuroscience